Iron Deficiency Anemia (IDA) is a prevalent global health issue. Two commonly used treatments for IDA are Iron Bisglycinate Chelate (FeBC) and polymaltose iron (FeP). These treatments are well-tolerated by patients and have a low occurrence of adverse effects. However, it’s important to note that FeBC and FeP differ significantly in their structures and bioavailability.
Objective: To compare the efficacy of oral supplementation with FeBC and FeP in anemic children.
Methods: In this double-blind study, children aged 1 to 13 years who were diagnosed with IDA were randomly divided into two groups: i) FeBC, supplemented with iron bisglycinate chelate, and ii) FeP, supplemented with polymaltose iron (3.0 mg iron/kg body weight/day for 45 days for both groups).
Results: Both treatments resulted in significant increases in hemoglobin levels, Mean Corpuscular Volume (MCV) and Cell Distribution Width (RDW) and in a reduction of transferrin levels, relative to initial values. However, only FeBC treatment significantly increased ferritin and Mean Corpuscular Hemoglobin (MCH) levels. A significant negative correlation was observed between the increase in ferritin and initial hemoglobin levels in the FeBC group, indicating that the absorption of FeBC is regulated by the body iron demand.
Conclusion: These results provide preliminary evidence to suggest a greater efficacy of FeBC than FeP in increasing iron stores.
PMID: 30280670 PMCID: PMC6416187 DOI: 10.2174/1573396314666181002170040
Source: José João Name 1, Añdrea Rodrigues Vasconcelos 2, Maria Cristina Valzachi Rocha Maluf 1